GlassScriptPhysician profile
Chandra V Vethody
NPI 1427432285
$1,153.12
in general payments reported to CMS, 2019-2025
12 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061 · Education: $91.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.21 |
| Education | $91.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $421.87 | 2025 | Dupixent |
| Inspire Medical Systems, INC. | $140.69 | 2025 | Inspire |
| Csl Behring | $110.46 | 2025 | Andembry, Haegarda, Hizentra |
| Genzyme Corporation | $108.15 | 2025 | |
| Novartis Pharmaceuticals Corporation | $95.49 | 2025 | |
| Glaxosmithkline, LLC. | $87.05 | 2025 | Nucala |
| Amgen INC. | $84.71 | 2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $31.26 | 2025 | Tezspire |
| Pharming Healthcare, INC. | $26.84 | 2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $16.33 | 2025 | Eohilia |
| Lilly USA, LLC | $15.85 | 2025 | Ebglyss |
| Genentech USA, INC. | $14.42 | 2025 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Vethody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.